drugset / Trial / NCT00393939
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.
Timeline
- Start
- 2007-02
- Primary completion
- 2010-02
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | 100 mg/m2 | — |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |